Faes Farma, S.A.
Spain · ES0134950F36 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Good
- Revenue +24% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 11% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 56% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
€610M
revenue
n/a
operating margin
€80M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | €439M | €451M | €494M | €610M |
| Net profit to shareholders | €90M | €92M | €111M | €80M |
| Earnings per share | €0.29 | €0.30 | €0.36 | €0.26 |
| Dividend per share | €0.06 | n/a | n/a | €0.04 |
| Cash from operations | €107M | €101M | €115M | €78M |
| Capital spending | €75M | €96M | €34M | €16M |
| Cash | €66M | €35M | €64M | €117M |
| Total assets | €726M | €777M | €853M | €1.3B |
| Equity | €602M | €663M | €727M | €746M |
What they do
In the company's own words, from the annual report.
fabricación y venta de productos farmacéuticos, así como la fabricación y venta de productos de nutrición y salud animal.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.